Скачать с ютуб Safety and tolerability of AMG 330, a bispecific T-cell engager, in adult patients with R/R AML в хорошем качестве

Safety and tolerability of AMG 330, a bispecific T-cell engager, in adult patients with R/R AML

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the safety and tolerability of AMG 330 in adults with relapsed/refractory (R/R) acute myeloid leukemia (AML). In a Phase I dose escalation trial (NCT02520427), AMG 330 elicited responses but was associated with toxicities such as cytokine release syndrome (CRS) and infusion reactions. Dr Ravandi is unsure whether this agent will move into further development, as focusing efforts on developing bispecific antibodies with AML-specific targets may confer greater therapeutic benefit. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.